BioNTech
An der Goldgrube 12
Mainz
D-55131
Germany
718 articles about BioNTech
-
The companies contend that their updated COVID-19 vaccines for the fall vaccination season can elicit strong immune responses against the virus’ currently dominant and emerging subvariants.
-
BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer
8/14/2023
BioNTech SE announced that the Supervisory Board has appointed James Ryan, Ph.D., to the Management Board as Chief Legal Officer, effective September 1, 2023.
-
DualityBio Expands Global Strategic Partnership with BioNTech to Accelerate Development of a Third Antibody-Drug Conjugate Therapeutics for Solid Tumors
8/7/2023
Duality Biologics Co. Ltd. announced that the company has expanded its collaboration with BioNTech SE to develop, manufacture and commercialize a third ADC candidate DB-1305 globally, excluding Mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region.
-
BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update
8/7/2023
BioNTech SE reported financial results for the three and six months ended June 30, 2023, and provided an update on its corporate progress.
-
BioNTech Completes Acquisition of InstaDeep
7/31/2023
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the completion of the acquisition of InstaDeep Ltd. (“InstaDeep”), a leading global technology company in the field of artificial intelligence (“AI”) and machine learning (“ML”).
-
BioNTech to Report Second Quarter 2023 Financial Results and Operational Update on August 7, 2023
7/24/2023
BioNTech SE will announce its financial results for the second quarter 2023 on Monday, August 7th, 2023.
-
Biotheus Announces Strategic Research Collaboration and Worldwide License Agreement with BioNTech
7/19/2023
Biotheus Inc. ("Biotheus") announced today that it has entered into a strategic research collaboration, option and worldwide license agreement with BioNTech SE ("BioNTech"), a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases.
-
CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights
7/13/2023
CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that it has strengthened its position in the ongoing patent litigations with Pfizer/BioNTech in Germany and the U.S. by expanding the scope of both cases by asserting new intellectual property rights.
-
Doer Biologics Announces License Agreement with BioNTech
7/11/2023
Zhejiang Doer Biologics Co., Ltd., a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, announced that it has entered into a license agreement with BioNTech SE.
-
BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC
6/29/2023
BioNTech SE and OncoC4, Inc. announced that the first patient with non-small cell lung cancer has been treated in a pivotal Phase 3 trial evaluating the companies’ next-generation anti-CTLA-4 antibody candidate BNT316/ONC-392.
-
While the German biotech that partnered with Pfizer on a COVID vaccine sees its first lawsuit, legal experts don’t expect similar cases in the U.S.
-
BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
6/2/2023
BioNTech SE and OncoC4, Inc., announced positive preliminary data from the ongoing Phase 1/2 trial with the companies’ anti-CTLA-4 antibody candidate, BNT316/ONC-392, in a patient cohort with metastatic, PD-1-resistant non-small cell lung cancer.
-
ADCs from BioNTech, Daiichi Sankyo and Merck are the subject of high-profile abstracts featured at the oncology meeting, along with Merck’s late-breaking Phase III non-small cell lung cancer data.
-
CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech
5/19/2023
Motion to transfer U.S. litigation to Eastern District of Virginia granted at CureVac's request and expected to significantly accelerate U.S. litigation timeline.
-
ASCO 2023 Spotlight: Claudin 6 Anticipated To Shine
5/17/2023
The escalating battle between Claudin 6 immunotherapies from Amgen, BioNTech and Context Therapeutics, and CLDN6 antibody-drug-conjugates from Daiichi-Sankyo and TORL BioTherapeutics will be a highlight of the upcoming 2023 American Society of Clinical Oncology Annual Meeting, taking place on June 2-6, 2023, in Chicago, IL.
-
After a brief slump, interest in ADCs is at an all-time high, highlighted by a handful of recent multi-million- and billion-dollar acquisitions.
-
The German biotech is trying to deepen its pipeline in cancer and other infectious diseases as COVID-19 markets contract and the international public health emergency comes to an end.
-
BioNTech Announces First Quarter 2023 Financial Results and Corporate Update
5/8/2023
BioNTech SE reported financial results for the three months ended March 31, 2023, and provided an update on its corporate progress.
-
BioNTech to Report First Quarter 2023 Financial Results and Operational Update on May 8, 2023
4/24/2023
BioNTech SE will announce its financial results for the first quarter 2023 on Monday, May 8th, 2023.
-
The lawsuit, brought by Arbutus Biopharma, marks the latest legal action in an ongoing battle for intellectual property underlying mRNA vaccines for COVID-19.